{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:17:15Z","timestamp":1791389835692,"version":"4.3.3"},"reference-count":27,"publisher":"Elsevier BV","issue":"50","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.vaccine.2012.09.027","type":"journal-article","created":{"date-parts":[[2012,9,23]],"date-time":"2012-09-23T14:00:11Z","timestamp":1348408811000},"page":"7315-7320","source":"Crossref","is-referenced-by-count":43,"title":["Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: A randomized, dose-escalation phase 1 study in adults"],"prefix":"10.1016","volume":"30","author":[{"given":"Nithya","family":"Gogtay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urmila","family":"Thatte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilima","family":"Kshirsagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Leav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Molrine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Cheslock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhash V.","family":"Kapre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad S.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"May (5)","key":"10.1016\/j.vaccine.2012.09.027_bib0005","first-page":"360","article-title":"Re-evaluating the burden of rabies in Africa and Asia","volume":"83","author":"Knobel","year":"2005","journal-title":"Bull World Health Organ"},{"issue":"March (1)","key":"10.1016\/j.vaccine.2012.09.027_bib0010","first-page":"32","article-title":"An epidemiological study of animal bites in India: results of a WHO sponsored national multi-centric rabies survey","volume":"38","author":"Sudarshan","year":"2006","journal-title":"J Commun Dis"},{"issue":"October (44)","key":"10.1016\/j.vaccine.2012.09.027_bib0015","first-page":"7140","article-title":"Rabies vaccines: WHO position paper \u2013 recommendations","volume":"28","year":"2010","journal-title":"Vaccine"},{"issue":"July (3)","key":"10.1016\/j.vaccine.2012.09.027_bib0020","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0001-706X(98)00038-2","article-title":"Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine","volume":"70","author":"Lang","year":"1998","journal-title":"Acta Trop"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2012.09.027_bib0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0264-410X(89)90003-0","article-title":"Adverse effects of equine rabies immune gobulin","volume":"7","author":"Wilde","year":"1989","journal-title":"Vaccine"},{"issue":"April (16)","key":"10.1016\/j.vaccine.2012.09.027_bib0030","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199904223401602","article-title":"Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group","volume":"340","author":"Kenny-Walsh","year":"1999","journal-title":"N Engl J Med"},{"issue":"May (8958)","key":"10.1016\/j.vaccine.2012.09.027_bib0035","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(95)91002-6","article-title":"Hepatitis C transmission associated with intravenous immunoglobulins","volume":"345","author":"Yu","year":"1995","journal-title":"Lancet"},{"issue":"October (42)","key":"10.1016\/j.vaccine.2012.09.027_bib0040","doi-asserted-by":"crossref","first-page":"6847","DOI":"10.1016\/j.vaccine.2010.08.034","article-title":"Socioeconomic status is a critical risk factor for human rabies post-exposure prophylaxis","volume":"28","author":"Fang","year":"2010","journal-title":"Vaccine"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2012.09.027_bib0045","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(11)70340-1","article-title":"Passive immunity in the prevention of rabies","volume":"12","author":"Both","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2012.09.027_bib0050","first-page":"375","article-title":"Elimination of human rabies in a canine endemic province in Thailand: five-year programme","volume":"81","author":"Kamoltham","year":"2003","journal-title":"Bull World Health Organ"},{"issue":"September\u2013October (5)","key":"10.1016\/j.vaccine.2012.09.027_bib0055","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4161\/mabs.1.5.9448","article-title":"Industrialization of mAb production technology: the bioprocessing industry at a crossroads","volume":"1","author":"Kelley","year":"2009","journal-title":"MAbs"},{"issue":"October (5)","key":"10.1016\/j.vaccine.2012.09.027_bib0060","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1089\/hyb.1991.10.547","article-title":"A rabies-specific human monoclonal antibody that protects mice against lethal rabies","volume":"10","author":"Enssle","year":"1991","journal-title":"Hybridoma"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2012.09.027_bib0065","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1086\/500470","article-title":"Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin","volume":"193","author":"Goudsmit","year":"2006","journal-title":"J Infect Dis"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2012.09.027_bib0070","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1348-0421.2010.00262.x","article-title":"Isolation and characterization of novel human monoclonal antibodies possessing neutralizing ability against rabies virus","volume":"54","author":"Matsumoto","year":"2010","journal-title":"Microbiol Immunol"},{"issue":"September\u2013October (5)","key":"10.1016\/j.vaccine.2012.09.027_bib0075","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4161\/hv.3.5.4386","article-title":"Use of neutralizing murine monoclonal antibodies to rabies glycoprotein in passive immunotherapy against rabies","volume":"3","author":"Muhamuda","year":"2007","journal-title":"Hum Vaccin"},{"issue":"11","key":"10.1016\/j.vaccine.2012.09.027_bib0080","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1371\/journal.pntd.0000542","article-title":"Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans","volume":"3","author":"Muller","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"issue":"April (15)","key":"10.1016\/j.vaccine.2012.09.027_bib0085","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.vaccine.2006.12.031","article-title":"Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates","volume":"25","author":"Sloan","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.09.027_bib0090","series-title":"Rabies in the Americas XIX","article-title":"Fully human monoclonal antibody 17C7 neutralizes rabies virus endemic to Asia","author":"Babcock","year":"2008"},{"key":"10.1016\/j.vaccine.2012.09.027_bib0095","series-title":"XVII international conference on rabies in the Americas","article-title":"Post-exposure prophylaxis (PEP) against Thai street rabies virus and Eurasian bat Lyssaviruses with purified chick embryo vaccine, pepsin-digested ERIG, human rabies immune globulin and a human monoclonal antibody (MAB 17C7)","author":"Lumlertdacha","year":"2006"},{"issue":"January\u2013February (1)","key":"10.1016\/j.vaccine.2012.09.027_bib0100","first-page":"18","article-title":"Frequency and causes for exclusion from randomization of healthy volunteers screened for a phase 1 study in India","volume":"25","author":"Gogtay","year":"2012","journal-title":"Natl Med J India"},{"issue":"December (4)","key":"10.1016\/j.vaccine.2012.09.027_bib0105","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.biologicals.2005.06.005","article-title":"The influence of homologous vs. heterologous challenge virus strains on the serological test results of rabies virus neutralizing assays","volume":"33","author":"Moore","year":"2005","journal-title":"Biologicals"},{"issue":"August (2)","key":"10.1016\/j.vaccine.2012.09.027_bib0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.antiviral.2011.06.002","article-title":"G glycoprotein amino acid residues required for human monoclonal antibody RAB1 neutralization are conserved in rabies virus street isolates","volume":"91","author":"Wang","year":"2011","journal-title":"Antiviral Res"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2012.09.027_bib0115","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1128\/AAC.43.5.1183","article-title":"Safety and pharmacokinetics of an intramuscular monoclonal antibody (SB 209763) against respiratory syncytial virus (RSV) in infants and young children at risk for severe RSV disease","volume":"43","author":"Meissner","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"March (1)","key":"10.1016\/j.vaccine.2012.09.027_bib0120","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1006\/biol.1997.0117","article-title":"Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies","volume":"26","author":"Lang","year":"1998","journal-title":"Biologicals"},{"issue":"November (47)","key":"10.1016\/j.vaccine.2012.09.027_bib0125","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1016\/j.vaccine.2008.08.050","article-title":"First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity","volume":"26","author":"Bakker","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.09.027_bib0130","series-title":"XX international conference on rabies in the Americas","article-title":"Evaluation of the safety and neutralizing activity of CL184, a monoclonal antibody cocktail against rabies virus, in a phase II study in healthy adolescents and children","author":"Quimbao","year":"2009"},{"issue":"4","key":"10.1016\/j.vaccine.2012.09.027_bib0135","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/11531860-000000000-00000","article-title":"Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review","volume":"28","author":"Prescott","year":"2010","journal-title":"Pharmacoeconomics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12013382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12013382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T00:38:44Z","timestamp":1562200724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12013382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":27,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0264410X12013382"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.09.027","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}